



**HAL**  
open science

## **Molecular Mechanisms of Trophoblast Dysfunction Mediated by Imbalance between STOX1 Isoforms**

Aurélien Ducat, Betty Couderc, Anthony Bouter, Louise Biquard, Rajaa Aouache, Bruno Passet, Ludivine Doridot, Marie-Benoîte Cohen, Pascale Ribaux, Clara Apicella, et al.

► **To cite this version:**

Aurélien Ducat, Betty Couderc, Anthony Bouter, Louise Biquard, Rajaa Aouache, et al.. Molecular Mechanisms of Trophoblast Dysfunction Mediated by Imbalance between STOX1 Isoforms. *iScience*, 2020, 23 (5), 10.1016/j.isci.2020.101086 . hal-03023054

**HAL Id: hal-03023054**

**<https://hal.science/hal-03023054>**


Submitted on 25 Nov 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Article

# Molecular Mechanisms of Trophoblast Dysfunction Mediated by Imbalance between STOX1 Isoforms



Aurélien Ducat,  
Betty Couderc,  
Anthony  
Bouter, ..., Jean-  
Luc Vilotte,  
Francisco Miralles,  
Daniel Vaiman

daniel.vaiman@inserm.fr

**HIGHLIGHTS**

STOX1, involved in preeclampsia, recognizes specific DNA sequences

Downregulation of STOX1 isoforms has limited effect on trophoblast gene expression

Overexpression of STOX1A and B leads to downregulation of some genes

Overexpression of STOX1A or STOX1B leads to opposite effects on other genes

**DATA AND CODE**

**AVAILABILITY**

GSE148088



## Article

## Molecular Mechanisms of Trophoblast Dysfunction Mediated by Imbalance between STOX1 Isoforms

Aurélien Ducat,<sup>1</sup> Betty Couderc,<sup>1</sup> Anthony Bouter,<sup>2</sup> Louise Biquard,<sup>1</sup> Rajaa Aouache,<sup>1</sup> Bruno Passet,<sup>3</sup> Ludivine Doridot,<sup>1</sup> Marie-Benoîte Cohen,<sup>4</sup> Pascale Ribaux,<sup>4</sup> Clara Apicella,<sup>1</sup> Irène Gaillard,<sup>1</sup> Sophia Palfray,<sup>1</sup> Yulian Chen,<sup>1</sup> Alexandra Vargas,<sup>1</sup> Amélie Julé,<sup>1</sup> Léo Frelin,<sup>2</sup> Julie Cocquet,<sup>1</sup> Camino Ruano San Martin,<sup>1</sup> Sébastien Jacques,<sup>1</sup> Florence Busato,<sup>5</sup> Jorg Tost,<sup>5</sup> Céline Méhats,<sup>1</sup> Paul Laissue,<sup>6</sup> Jean-Luc Vilotte,<sup>3</sup> Francisco Miralles,<sup>1</sup> and Daniel Vaiman<sup>1,7,\*</sup>

## SUMMARY

**STOX1 is a transcription factor involved in preeclampsia and Alzheimer disease. We show that the knock-down of the gene induces rather mild effect on gene expression in trophoblast cell lines (BeWo). We identified binding sites of STOX1 shared by the two major isoforms, STOX1A and STOX1B. Profiling gene expression of cells overexpressing either STOX1A or STOX1B, we identified genes downregulated by both isoforms, with a STOX1 binding site in their promoters. Among those, STOX1-induced Annexin A1 downregulation led to abolished membrane repair in BeWo cells. By contrast, overexpression of STOX1A or B has opposite effects on trophoblast fusion (acceleration and inhibition, respectively) accompanied by syncytin genes deregulation. Also, STOX1A overexpression led to abnormal regulation of oxidative and nitrosative stress. In sum, our work shows that STOX1 isoform imbalance is a cause of gene expression deregulation in the trophoblast, possibly leading to placental dysfunction and preeclampsia.**

## INTRODUCTION

STOX1, storkheadbox 1, a transcription factor belonging to the enlarged FOX family, was discovered in 2005 by the association of genetic polymorphisms located inside the open reading frame of the gene with familial forms of preeclampsia (PE) (van Dijk et al., 2005), a placental disease inducing systemic endothelial dysfunction, leading to hypertension and proteinuria in pregnant women. From then on, STOX1 was found to play important roles in cell proliferation (Abel et al., 2012; Nie et al., 2015; van Abel et al., 2011), migration/invasion mechanisms (Tyberghein et al., 2012; van Dijk et al., 2010), and oxidative/nitrosative stress balance (Doridot et al., 2014). Several reports also connected STOX1 with Alzheimer disease (van Abel et al., 2012a, 2012b; van Dijk et al., 2010), perhaps through a specific role in neurogenesis via transcriptional repression of the MATH1 helix-loop-helix transcription factor (Joubert et al., 2016). STOX1 exists under two major isoforms, STOX1A (the most complete, encompassing in particular a DNA-binding domain and a transactivator domain) and STOX1B, which does not encompass the transactivator domain (van Dijk et al., 2005). To note, among the striking specificities of this gene, its sequence appears to encompass a highly conserved Piwi-interacting RNA cluster (Chirn et al., 2015) that may be involved in STOX1-induced gene regulation. However, the precise mechanisms by which STOX1 controls gene expression are still not well known. We recently hypothesized that the two isoforms could compete for the same DNA binding site(s), thereby inducing opposite physiological responses (Vaiman and Miralles, 2016). This question of the balance between STOX1A and STOX1B is at the center of the present study.

The cytotrophoblast is a placental-specific cell type. The trophoblast, the cell layer surrounding the mammalian embryo at the blastocyst stage, consists of cytotrophoblasts. As soon as implantation occurs, around 8 to 9 days post-fertilization in humans, cytotrophoblasts fuse and generate a syncytium called the syncytiotrophoblast (Orendi et al., 2010; Pidoux et al., 2012). This is accompanied by wide modifications of cell physiology, with increased concentration of cAMP levels, triggering a cascade starting from the

<sup>1</sup>Institut Cochin, U1016, INSERM, UMR 8504 CNRS, Université Paris Descartes, Paris 75014, France

<sup>2</sup>Institute of Chemistry and Biology of Membranes and Nano-objects, UMR 5248, CNRS, University of Bordeaux, IPB, 33600 Pessac, France

<sup>3</sup>Université Paris-Saclay, INRAE, AgroParisTech, UMR1313-GABI, 78350, Jouy-en-Josas, France

<sup>4</sup>Department of Gynecology Obstetrics, Faculty of Medicine, University of Geneva, 1205 Geneva, Switzerland

<sup>5</sup>Laboratory for Epigenetics and Environment, Institut de Biologie François Jacob, Commissariat à l'Énergie Atomique, Evry 91057, France

<sup>6</sup>Biopas Laboratoires, BIOPAS GROUP, Bogotá, Colombia

<sup>7</sup>Lead Contact

\*Correspondence: daniel.vaiman@inserm.fr

<https://doi.org/10.1016/j.isci.2020.101086>



activation of protein kinase A and eventually activating the trophoblast-specific transcription factor glial cell missing homolog 1 (*GCM1*). Among *GCM1* targets is *ERWW1*, which is a gene of endoretroviral origin encoding syncytin 1 that plays a pivotal role in placental cell syncytialization (Mallet et al., 2004). Cytotrophoblast fusion is accompanied by a complete modification of the expression profile of numerous genes, notably chorionic gonadotrophin chain beta (*CGB*), encoding the  $\beta$  chain of the human CG (hCG) (Shankar et al., 2015). Hence, the detection of hCG is used to diagnose early pregnancy in pregnancy tests.

After implantation, the villous tree develops via ramification, mesenchyme increase, and angiogenesis inside each villus. The developing placenta is bounded by a syncytiotrophoblast layer, under which villous trophoblasts reside. These cells serve as a reserve for regenerating the syncytiotrophoblast during human pregnancy. In humans, some trophoblasts become extravillous: some constitute plugs obstructing the maternal arteries during the first trimester of pregnancy (Carbillon et al., 2001), whereas some others invade the maternal spiraled arteries by exchanging their place with endothelial cells and modifying the arterial phenotype and contractility (Chen et al., 2012). Cell models of the two major types of trophoblasts, i.e. close to extravillous trophoblasts (EVTs) and close to villous cytotrophoblasts (VCTs), are available. Among those, BeWo cells are particularly interesting tools to analyze VCT physiology because BeWo cells can fuse into syncytiotrophoblasts when the cAMP cascade is induced by forskolin. This model has been extensively used to characterize the mechanisms of trophoblast fusion (Azar et al., 2018).

In this study, we aimed at elucidating the importance of the *STOX1A/STOX1B* imbalance in the function of this transcription factor. We first carried out a knock-down experiment in BeWo cells with and without forskolin-induced fusion, showing a very mild effect of this downregulation on genes relevant for trophoblast biology. To progress further, we identified the DNA sequences recognized by *STOX1* and present evidence indicating that *STOX1* is a major regulator of *bona fide* trophoblast function through the *STOX1A/STOX1B* imbalance that induces trophoblast dysfunction by various molecular mechanisms, affecting major pathways required by the placenta to work normally, such as syncytialization, membrane repair, or redox equilibrium. Deregulation of gene expression induced by *STOX1* occurred via its conventional action as a transcription factor, binding to a promoter at specific sequences, and thereby regulating gene expression, but possibly also via epigenome alterations leading to modifications of the methylation profile for certain genes. In sum, we show here that *STOX1* is a transcription factor acting originally through the balance between two isoforms, probably regulated by alternative splicing and competing for the same binding site.

## RESULTS


### Mild Effects of *STOX1* Downregulation on the Expression of Pivotal Placental Genes

Knock-down of *STOX1* (all isoforms, Figure S1) was carried out by siRNA treatment and the effect studied in control BeWo cells treated or not with forskolin, an activator of the cAMP cascade known to induce syncytialization in this trophoblastic cell model. The expression of seventeen genes relevant for trophoblast function (including *STOX1*) was then assessed, using RT-qPCR (Figure 1, Table S1). These genes included genes involved in trophoblast fusion (*Syncytin1*, *Syncytin2*, *CGA*, *TGM2* (Robinson et al., 2007)), membrane repair (*ANXA1*, *ANXA2*), oxidative stress (*NOS3*, *CAV1*, *CAPN6*), protein dynamics (*GPR146*, *PSMG1*, *WRB*, *ITIH5*), apoptosis regulation (*SEMA6A* (Pantham et al., 2012)), cell cycle (*BRWD1*), and chromatin activity (*HMGN1*).

*STOX1* mRNA level was downregulated by forskolin treatment (by 65%), as well as by the siRNA by 61% (Figure 1). The downregulation of *STOX1*, along with cell differentiation induced by forskolin, is consistent with reports mentioning *STOX1* as a proliferation/differentiation regulator in several tissues (Nie et al., 2015; Zhang et al., 2016). Among the putative target genes, 14 genes were strongly affected at the expression level by forskolin treatment (*Syncytin2*, *CGA*, *ANXA1*, *ANXA2*, *GPR146*, *CAPN6*, *NOS3*, *CAV1*, *ITIH5*, *TGM2*, *SEMA6*, *PSMG1*). The *STOX1* knockdown affected more mildly only three genes (*CAPN6*, *BRWD1*, and *ITIH5*). The interaction effect between the two factors was not significant, in any gene system. This mild effect of *STOX1* inhibition led us to analyze in more detail the mechanism of action of this transcription factor, by identifying its DNA-binding sequence and evaluating the effect of a *STOX1A* versus *STOX1B* imbalance.

### Identification of the *STOX1* Binding Site

We used the PCR-selection procedure (Pollock, 2001) based on five rounds of PCR enrichment of oligonucleotides presenting a random sequence of 26 bp in their middle, after immunoprecipitation of the






**Figure 1. Impact of STOX1 Knock-Down on Genes Involved in Trophoblast Function in BeWo Cells, with or without Forskolin-Induced Fusion (FSK and CTL, Respectively)**

For each gene the two first bars are mock-transfected and the two next siRNA-transfected. \* relates to significance for the forskolin effect, and # the siRNA effect (ANOVA 2-factors—STOX KD and forskolin treatment—for each gene, \* and #:  $p < 0.05$ , \*\* and ###:  $p < 0.01$ , and \*\*\* and ####:  $p < 0.001$ ).

cognate transcription factor. With lack of excellent validated antibodies for STOX1, we cloned a flagged STOX1B gene and overexpressed the chimeric protein in COS-7 cells, a cell model that is very easily and efficiently transfected by classical lipofectamin procedures (more than 90% efficiency). Fifty-eight sequences were obtained, and MEME (Bailey et al., 2009) revealed two significantly enriched conserved DNA elements, further called STOX responsive element 1 (STRE1; CATYTCACGG) and STOX-responsive element 2 (STRE2; GGTGYGGAMA), with E-values of  $4.1 \times 10^{-9}$  and  $1.5 \times 10^{-11}$ , respectively. In the control experiment, 44 sequences were obtained, with no significant enrichment in a specific sequence (best E-value =  $1.8 \times 10^2$ ). In ~80% of the sequences, STRE1 and 2 were present together in the 26-bp-enriched fragment (Figure 2A).

To validate the identified sequences, we used gel-shift assays (Figure 2B). We designed biotinylated oligonucleotides presenting three copies of STRE1 or three copies of STRE2 and used them in the assays, incubating these probes with COS-7 and JEG-3 protein extracts after transfection by a STOX1A- or B-expressing vector (as a model of cytotrophoblast cells that are unable to fuse) and with extracts from BeWo cells stably transfected with STOX1A or STOX1B expression vectors (see below). We did not observe specific retarded bands corresponding to STOX1A or B binding to STRE2 (data not shown). By contrast, STRE1 revealed clear specific bindings to a band of apparent high molecular weight when STOX1A was overexpressed and to a band of lower molecular weight when STOX1B was overexpressed, and this was true in the three cell models analyzed. The co-occurrence of STRE1 and STRE2 in most of the enriched fragments suggest that STRE2 enhances the binding of STOX proteins to STRE1, without being directly bound.

To evaluate the ability of these sequences to drive transcription, we cloned STRE2 and 1 alone or together in front of the luciferase reporter gene and analyzed their ability to confer expression modifications in two cell models (COS-7 and JEG-3, that are commonly used in transient transfections), with similar results (as shown for JEG-3 cells in Figure 2C). STRE1 alone could be induced with STOX1A overexpression ( $1.2$ -



**Figure 2. Identification of STOX1A Binding Site**

(A) Target sequences identified by MEME after PCR selection experiments (see text). The 2 sequences were analyzed by gel-shift experiments. Each experiment was reproduced three times.

(B) In the left panel, STOX1A or B was overexpressed transiently in COS-7 cells. A small complex was retarded when STOX1B was transfected (black arrow), and a larger complex was retarded when STOX1A was overexpressed (red arrow). The anti-flag antibody abolished the binding, which suggests that the antibody tends to compete on the DNA binding domain. In the center panel, STOX1A or B with six flags (6F-STOX1A) was transiently transfected in JEG-3 cells. In these cases, a specific complex was detected (red arrow), together with a smaller complex corresponding to STOX1B, spontaneously present in JEG-3 trophoblast cells (black arrows, absent in COS-7 cells with low basal expression level of STOX1). The competition with homologous (STRE1 cold) or mutant sequences (mSTRE1 cold) revealed that the band corresponding to the highest molecular weight was not specific, whereas the second (corresponding to STOX1A) and the third (corresponding to STOX1B) appear specific. The right panel presents a gel-shift experiment with protein extracts from BeWoA and BeWoB cells. As expected from the known expression of STOX1 at a basal level in these trophoblast cells, STOX1A and B bands appear in both cell lines, but their ratio is reversed, as shown after quantification above the gel shift. The retarded band corresponding to STOX1A is 2.15-fold more intense than the STOX1B band in BeWoA cells. By contrast in BeWoB, the STOX1B band is 1.34-fold more intense than the STOX1A band in BeWoB.

(C) STRE1 and 2 were cloned in both orientations, isolated or together in front of a CMV-luciferase reporter plasmid, and transfected in JEG-3 cells. The clones are called 3R, 4R, 7F, and 7R and correspond to various constructions harboring STRE1, STRE2, or both, in forward or reverse orientations, compared with the sequences firstly identified. Data are mean  $\pm$  SEM from four experiments and normalized against an empty CMV vector ( $n = 4$ , 4-plicates to 6-plicates, for each construction ANOVA 1 factor, followed by Dunnett post-hoc test, \*\*\* $p < 0.001$ ).

fold,  $p < 0.01$ ), but this induction was enhanced with a construction containing both STRE1 and 2 to 1.59-fold ( $p < 0.001$ ); STOX1B overexpression appeared unable to mediate this increased expression. We carried the same type of experiments using STRE1 and STRE2 mutants cloned in front of the luciferase reporter. In this case, STOX1A overexpression was unable to increase luciferase activity (Figure S2).



Despite the observed effect of STOX1A on STRE1+2 constructs, the observed induction levels cannot solely account for what was observed in the cell transcriptome experiments previously published, with maximal induction levels reaching >15- to 20-fold in JEG-3 cells overexpressing STOX1A (Rigourd et al., 2008).

**Implications of the Discovery of the STOX1 Binding Site in the Context of a Villous Trophoblast Cell Model**

Three different stable cell lines derived from the BeWo choriocarcinoma (homologous to villous trophoblasts, VCTs) were created for the present study. These three BeWo-derived stable cell lines overexpress either STOX1A or STOX1B or have only the empty expression vector conferring Geneticin resistance. These cell lines were called BeWoA, B, and C, respectively. The relative expression of STOX1A and STOX1B was analyzed with specific qPCR primers, revealing an overexpression of ~25-fold for STOX1A in BeWoA compared with BeWoC, and of ~6-fold for STOX1B in BeWoB cells compared with BeWoC cells. Although the degree of overexpression differs for the two isoforms, the increase is clearly enough to perturb drastically the balance between the two isoforms in a given cell line.

We performed transcriptome analysis of the three cell lines before and after forskolin-induced cell fusion. PCA analysis separated clearly the different conditions (Figure 3A). The data were submitted to GEO Profiles under the accession number GSE148088 and analyzed using the Transcriptome Analysis Console from Affymetrix (ThermoFisher). Genes that are studied in this paper are presented as a list in Table S2. The first axis of the PCA (38.6% of the variance) encapsulates the variation induced by forskolin treatment leading to cell fusion, with different trajectories dependent on the enhanced expression of STOX1A or STOX1B. The number of modified genes according to the conditions (Figure 3B) ranged from 858 (comparison between BeWoB and BeWoC) to 4,198 (comparison between BeWoA+ FSK and BeWoA). The left part of the figure (three groups of histograms) shows that following forskolin treatment, there was a systematic bias toward downregulated genes. The right part of the figure (four groups of histograms) presents the changes induced by STOX1A or STOX1B overexpression, with or without forskolin. In these cases, there was a systematic excess of downregulated genes, as well.

Next, we wished to study whether the presence of STRE1 and/or STRE2 in a gene promoter was associated with deregulation when STOX isoforms were overexpressed. Bioinformatics analysis of promoters using EPD (Eukaryotic Promoter Database, <https://epd.vital-it.ch/index.php>) was performed to search for





**Figure 3. Transcriptome Analysis of BeWo Cells (BeWoC: Controls, BeWoA: with STOX1A Overexpression, BeWoB: with STOX1B Overexpression)**

(A) PCA analysis successfully clusters the cells according to their expression and the forskolin treatment effects. (B) Differential analysis of gene expression following forskolin treatment (three categories at the left part of the figure) and comparing overexpressing versus control cells (four categories on the right side). In gray histograms are the total number of modified genes, in red the upregulated genes, and in green the downregulated genes (threshold  $>1.5$  or  $<1.5$ ,  $p < 0.05$ ).

STRE1 and STRE2 motifs in the  $-1,000$  bp to  $+200$  bp region of genes around the ATG codon; this resulted in 1,688 genes with a STRE1 sequence, 3,797 with a STRE2 and 444 encompassing both sequences (Figure 4A). By a contingency  $\chi^2$  analysis, we compared the gene deregulation induced either by STOX1A or STOX1B, in these gene subsets, with the alterations counted at the transcriptome level (21,448 genes). The log of the p value was plotted for each comparison and showed that there was a significant enrichment in deregulated genes in almost every situation (Figure 4B), except for STRE2-containing promoters when STOX1A was overexpressed under forskolin treatment. In sum, these results suggest that the increased concentration of STOX1A or STOX1B in the cells tend to trigger their binding sites with concomitant gene expression alterations.


We performed a Gene Set Enrichment Analysis (GSEA) using the String online tool (<https://string-db.org/cgi>) (Szkarczyk et al., 2019) on the subset of genes encompassing either STRE1 or STRE2 in the different comparisons toward the BeWo control cells (BeWoC), with or without forskolin. Although no significant ontology clustering was obtained for STRE1-encompassing gene promoters, genes encompassing STRE2 in their promoters and modulated by STOX1A were significantly enriched in “metallothionein” and “RNA metabolism” genes. To note, *MT1L*, *MT2A*, *MT1E*, *MT1A*, *MT1B*, *MT1G*, *MT1H*, *MT1X*, *MT1M*, *MT1F*, and *MT1P* were all downregulated by STOX1A 17.86-, 17.35-, 15.88-, 14.87-, 12.62-, 9.77-, 9.48-, 6.24-, 6.15-, 4.3-, and 2.91-fold, respectively. Most of these genes are located at 16q13, strongly suggesting that STOX1A regulates the expression of this genomic region. The possible consequences of this deregulation on the management of oxidative stress will be described below. When STOX1B is overexpressed the enriched ontology is “Cellular response to DNA damage/DNA repair.” In the presence of forskolin, we found an enrichment in the terms “Mitotic cell processes,” “DNA repair,” and “rRNA processing” when STOX1A is overexpressed. Finally, when STOX1B is overexpressed in the presence of forskolin, the ontology enrichment identifies the terms “DNA repair” and “RNA metabolism.” The downregulation of metallothionein genes specifically by STOX1A without induction of fusion by forskolin suggests that these BeWoA cells will be more prone to oxidative stress, because metallothioneins are major antioxidant molecules (RuttKay-Nedecky et al., 2013).

In a next step of the analysis, we identified among the 100 most deregulated genes in each of the four comparisons, transcripts that were deregulated in all the experimental conditions (overexpression of STOX1A or STOX1B  $\pm$  forskolin treatment), as summarized in Table 1.

All these genes were systematically downregulated. We noticed that some were characterized by a decreased expression triggered indifferently by the overexpression of STOX1A or STOX1B, generally without much influence of forskolin treatment. This was the case for *BRWD1*, *HMG1*, *PSMG1*, *CAPN6*, *TGM2*, and *ITIH5*. Systematic filtering genes harboring the same type of profile allowed us to aggregate to this list four additional genes that were not extracted by the promoter database screening—*ANXA1*, *GPR146*, *SEMA6*, and *WRB*. The expression profile of these genes is presented in Figure 5A.

Analysis of the promoters of these genes by MEME revealed an enrichment of specific sequences that were present in almost all the promoters; the two most conserved were associated in close vicinity in six out of ten promoters (Figure 5B). This prompted us to synthesize a probe including both motifs (Figure 5C).

In gel-shift experiments (Figure 6), carried out either in HeLa cells transiently transfected with either STOX1A or STOX1B or in the BeWo cell lines stably transfected (BeWoA and BeWoB, or control BeWoC), we could observe two complexes, independent of the overexpression of STOX1A or B. Non-biotinylated STRE1 (“cold”) was able to compete out only complex 2, whereas STRE2 could suppress complex 1 (and complex 2 as well, showing that this complex is not specific, being removed by any cold competitor). One interpretation is that Complex 1 contains a STRE2 binding site. Sequence reanalysis of the probe revealed the presence of a GGCRYGG sequence (in purple in Figure 5C), which, although not strictly identical



**Figure 4. The Occurrences of STRE1/STRE2 in Gene Promoters and Gene Expression Deregulation in the BeWo Cells Overexpressing STOX1 Isoforms**

(A) Bioinformatics analyses of promoters of human genes for the presence of STRE1 and/or STRE2 from the EPD database. The Venn diagram allows to identify 444 promoters encompassing both sequences.

(B) Deregulations of genes encompassing STRE1, STRE2, or both sequences in their promoters. The dashed line represents the significance threshold ( $p < 0.05$ ). The gene deregulations at the genome level were calculated from the ~21,000 genes present in the microarray.

to STRE2 (GGTGYGGAMA), is very similar. In addition, the STRE2 consensus percentages defined by the MEME software following the PCR-selection experiment were 100, 100%, 74%, 78%, 52%, 100%, and 100% at each of the seven first-base position, respectively. This indicates that the motif GGNNNGG is the main sequence recognized by a putative STRE2-binding factor.

As a paradigm of this group of genes downregulated indifferently by the two STOX1 isoforms, we studied in more detail the *HMGN1* promoter. *HMGN1* encodes a protein associated to active chromatin and to transcription activation, which justifies our focus on this gene. We first evaluated by RT-qPCR the impact

In the 100 Most Downregulated with STRE1					In the 100 Most Downregulated with STRE2				
	A vs C	B vs C	A-FSK versus C-FSK	B-FSK versus C-FSK		A versus C	B versus C	A-FSK versus C-FSK	B-FSK versus C-FSK
BRWD1	-31.83	-34.79	-76.89	-56.89	FSTL3	-50.93	-17	-42.36	-4.96
TFRC	-17.99	-2.98	-79.5	-2.54	CAPN6	-41.84	-34.7	-76.73	-123.56
HMGN1	-17.06	-13.13	-13.19	-12.45	KRT7	-23.67	-2.56	-64	-9.71
PSMG1	-13.77	-13.31	-217.86	-95.26	HMGN1	-17.06	-13.1	-13.19	-12.45
MDM2	-10.49	-3.35	-12.3	-3.24	TNFSF10	-16.07	-4.34	-2273.24	-11.68
C19orf43	-5.33	-2.14	-6.92	-2.76	EGFR	-11.3	-5.22	-11.02	-6.83
PLEC	-5.29	-1.98	-5.11	-3.7	TGM2	-10.78	-7.99	-6.4	-6.72
DYNLL1	-5.06	-1.74	-7.29	-3.3	ATG7	-6.26	-2.91	-11.17	-3.93
ELF4	-2.79	-1.78	-8.57	-3.46	ITIH5	-5.12	-4.63	-8.58	-5.39
NT5DC3	-2.7	-1.91	-4.42	-2.92	CAV1	-3.74	-7.49	-110.91	-22.48
SLC6A8	-2.43	-1.94	-26.12	-2.74					

**Table 1. Deregulation of STRE1/2 Encompassing Genes (Fold Change)**

of STOX1A and STOX1B overexpression on HMGN1 expression levels in extravillous trophoblast models (JEG3 overexpressing STOX isoforms) that were previously described (Rigourd et al., 2008). Surprisingly, in this cell model HMGN1 was strongly induced by STOX1A and STOX1B overexpression (1300-fold and 200-fold, respectively), whereas in the villous trophoblast model BeWo, it was downregulated (Figure 7A, left). The expression of HMGN1 was also enhanced in mouse placentas overexpressing STOX1A, the base for a previously published preeclampsia model (Figure 7A, center). By contrast, in human placentas, HMGN1 was significantly downregulated in preeclamptic samples (Figure 7A, right). This observation is consistent with the fact that human placentas samples are collected from villous material and hence do not contain extra-villous trophoblasts, which could explain why the human placenta responds in preeclampsia similarly to BeWo cells (as a proxy to villous trophoblast).



Another dimension of the regulation of HMGN1 could be of epigenetic nature, because the first exon of the gene encompasses a CpG island as shown in Figure 7B. We performed a ChIP-qPCR experiment after immunoprecipitation of Flag-STOX1A or Flag-STOX1B transfected in JEG-3 cells (four replicates), leading to a significant enrichment of 3-fold over the empty plasmid for STOX1A (Figure 7C). This binding was consistent with the presence of a STRE1 binding site in this promoter. We also cloned two fragments of the HMGN1 promoter in front of the luciferase reporter gene (831 and 2,192 bp, Figure 7B). We did not observe strong HMGN1 mRNA level modification fostered by STOX1 overexpression, either using the short or the long version of the promoter that has been cloned. However, once the promoter was methylated *in vitro*, STOX1B as well as STOX1A were able to downregulate the long promoter to one-fourth of the basal expression level (Figure 7D). This shows that transcription regulation by STOX1 is modulated by the epigenetic context at least for some genes.

### Physiological Consequences of Gene Deregulations in Cells Overexpressing STOX1A or STOX1B

After this genomic search for STOX1 binding sites and evaluation of their direct impact on gene expression, we explored the physiological consequences of the imbalance of the two isoforms, STOX1A and STOX1B. The three fields that were explored are (1) cell membrane repair in trophoblasts, (2) regulation of trophoblast fusion into syncytiotrophoblast, and (3) deregulation of oxidative/nitrosative stress.

#### Membrane Repair and STOX1 Expression

Annexins are pivotal to mechanisms of membrane repair (Boye and Nylandsted, 2016). Annexin A1 was one of the most downregulated genes by both STOX isoforms in the microarray experiment (Figure 5A). This downregulation was confirmed at the protein level (Figure 8A). Previously it was shown that classical



**C**

Probe for gel-shift (sequences 1 + 2)

YTGAGSYCAGGAGTTYGAGACCAGCCTGGSCAACATRGHGARACnnnnGCYRGGCR  
YGGTGGCKSACGCCTGTAATCCAGCWMYTTGGGAGGCYGAG

**Figure 5. Identification of Common Binding Sites in the 10 Genes Most Strongly Downregulated by Both STOX1A and B in BeWo Cells, with or without Induction of Fusion by Forskolin**

(A) The 10 genes were identified from the microarray analysis by screening for profiles similar to ANXA1.  
 (B) MEME analysis of the 10 promoter regions (~5,000 bp) revealed common motifs in nine of them. The two most significantly enriched motifs were generally found in common (light blue and red).  
 (C) A biotinylated probe was synthesized for gel-shift experiments. A STRE2 element was found in the red part of the motif and is underlined in purple.


BeWo cells were perfectly able to repair their plasmic membrane following a laser-induced lesion and that annexins and especially Annexin A5 is requested for this fundamental process (Carmeille et al., 2015).

We first explored the capabilities of membrane repair in JEG-3 cells. The monitoring of the rupture and membrane repair was carried out by recording FM1-43 fluorescence images, as previously described (Bouter et al., 2011; Carmeille et al., 2017). When the cell repairs its membrane, the fluorescence stagnates, as represented for BeWo cells in curves of Figure 8F. Unexpectedly, we discovered that JEG-3 cells were totally unable to repair their membranes and showed a continuous and large increase of the intracellular fluorescence intensity (Figures 8B and 8F; JEG3A and JEG3C). This deficiency in membrane repair was independent from STOX1A overexpression, which was about 20-fold the basal level in JEG3A cells, while JEG3C cells are controls (Figure 8F).


BeWoC cells present membrane repair ability as native BeWo cells, as shown in Figures 8C, 8F, and 8G. However, when STOX1A or STOX1B are overexpressed, the repair does not occur anymore (Figures 8D, 8E, and 8G). A closer look shows that intracellular vesicles do appear nearby the damaged membrane but are not able to patch it, leading to the leak of intracellular material (Figure 8H). This result is in agreement with the role proposed for Annexin A1, which may aggregate intracellular vesicles to form the lipid patch (Lennon et al., 2003).

*Regulation of Trophoblast Fusion by STOX1 Isoforms*

Syncytialization is a major developmental pathway for villous trophoblasts. Placental-specific fusogen genes (syncytins) were identified in all the species presenting a placenta and are crucial for trophoblast



**Figure 6. DNA-Protein Interactions at the Promoters of Genes Down-regulated by either form of STOX1**  
 Gel shift experiments using the probe described in Figure 7 in two models: HeLa cells transiently transfected with STOX1A or B and BeWo cell models used in the present study. In both cases, two complexes of similar molecular weight appeared. The first complex was removed exclusively by competition with excess STRE2, but STRE1 was unable to remove it. The second complex was removed nonspecifically whatever the competitor used. Thus, complex 1 is bound by a protein binding to STRE2. The absence of difference visible between the BeWoA, B, and C shows that this protein is not related to STOX1 (see text).



**Figure 7. Analysis of HMGN1 Expression in Cells and Placentas**

(A) The induction ratio was calculated from qRT-PCR: left panel, for JEG-3 cell lines overexpressing STOX1A (JEG-3A) or STOX1B (JEG-3B) relative to control cells (JEG-3C); middle panel, the same analysis for mouse placentas; right panel, the same analysis for human placentas, showing a significant decrease of *HMGN1* expression in human preeclamptic placentas (see text).

(B) A CpG island is located in the promoter and first exon of *HMGN1*, as shown by the CpG density presented in the graph; below are the structure of the part of the *HMGN1* promoter that was partially cloned in a Dual-Glo Luciferase reporter vector. Two versions of the promoter (short = 831 bp and long = 2,192 bp) were amplified encompassing one STRE2 and one STRE1 binding element separated by 70 bp. The density in CG dinucleotide was evaluated by counting windows of

**Figure 7. Continued**

10 bp and the representation is smoothed on five consecutive densities. The positions of the ATG initiation codon and the two STRE binding sites are relative to the figure.

(C) ChIP qPCR analysis of STOX1A able to bind directly to the HMGN1 promoter and to the F3 promoter.

(D) Two versions (long and short, of 2,192 and 831 bp, respectively) of the *HMGN1* promoter were cloned in a luciferase reporter plasmid, and luciferase activity was measured after co-transfection with an expression plasmid (empty [pCMX] or overexpressing STOX1B or A). Data are mean  $\pm$  SEM from three experiments. Tested by student t tests compared with control conditions in A, or ANOVA 1-factor followed by Dunnett post-hoc test for C and D. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .

fusion (Cornelis et al., 2015, 2017). Besides, one of the major functions of the fused trophoblast is the production of pregnancy-specific hormones, in particular hCG, a dipeptide obtained from the transcription of the *CGA* and *CGB* genes. There may exist links between membrane repair and cell fusion mechanisms (Omata et al., 2013). All these elements prompted us to study the relevant fusogen gene expression in the context of the cell trophoblast model. In control BeWoC cells, we observed that, as expected, forskolin treatment massively increases the expression of *Syncytin 1 and 2* (*ERVW-1*- x 3.59-fold and *ERVFRD1*- x 3.19-fold) (Figure 9A). Besides, *ERVV1* and *ERVV2* were induced as well (x 5.15- and x 3.61-fold). Strikingly, the induction level was much higher in BeWoA cells (5.7-, 62.9-, 69.5-, and 72.7-fold, for *ERVV1-Syncytin1*, *ERVV1*, *ERVFRD1-Syncytin2*, and *ERVV2*, respectively) than in control BeWoC cells. By contrast, the induction in BeWoB cells amounted only to 1.5, 4.7, 1.6, and 3.0, for the four genes, respectively.

Trophoblast fusion is associated to induction of the *CGB* gene family located as a cluster on chromosome 19, encompassing in this order—*CGB3*, *CGB2*, *CGB1*, *CGB5*, *CGB8*, and *CGB7* (Morrish et al., 1998; Pidoux et al., 2012). The expression levels of five of these genes are summarized in Figure 9B, in the three BeWo cell lines that were generated. Strikingly, although the basal level of expression was similar in the three cell lines, their induction following forskolin treatment was ~100-fold in BeWoA cells and around 50-fold in BeWoC cells but did not change significantly in BeWoB cells.


The cell fusion was evaluated by immunofluorescence of beta-catenin after forskolin treatment. Classical counting analyzing 10–20 fields in three independent experiments is summarized in Figure S3. Compared with control cells, the fusion index was significantly increased in BeWoA ( $p = 6.2 \cdot 10^{-3}$ ) but not statistically decreased in BeWoB cells despite a systematic trend in all the experiments ( $p = 0.071$ ). To automatize the quantification of the fusion we used the xCELLIGENCE system, which measures in real time the impedance in each well of a 96-well plate. The results indicate that BeWoA cells have a retarded growth when they are in culture (Figure 9C). We observed that forskolin treatment induces a reduction of the impedance (from which a cell index is calculated, see Figure 9D), associated with the increase in cell fusion observed by conventional methods. When fusion is induced by forskolin, BeWoC cells start to fuse after 9 h in culture; the decrease of impedance is accelerated in BeWoA and delayed in BeWoB cells, consistently with a decreased fusion efficiency in BeWoB cells. Our results suggest that STOX1A and STOX1B have opposite effects on cell fusion and differentiation (*CGB* gene expression). STOX1A accelerates and amplifies the fusion of the villous trophoblast into syncytiotrophoblast, whereas STOX1B limits or slows down this process.

### Deregulation of Oxidative/Nitrosative Stress

Oxidative stress is a major component of placental diseases (for a recent review, see for instance (Aouache et al., 2018)). Along with the observation reported above that STOX1 induces massive alterations of hypoxia sensing (Doridot et al., 2014), which is a major issue in the generation of oxidative stress, this prompted us to analyze the regulation of oxidative/nitrosative stress features in the BeWo cell models, under forskolin treatment or control treatment (DMSO vehicle).

In a first analysis, we evaluated the level of carbonylated proteins, which measures protein oxidation (a classical proxy of oxidative stress, Figure 10A). In basal conditions, the level of protein carbonylation (normalized relatively to  $\beta$ -tubulin) was similar between control BeWoC and BeWoB, whereas the basal level of carbonylation was about 3-fold higher when STOX1A was overexpressed. In BeWoC and BeWoB, forskolin treatment induced an increase in carbonylation of about 5- to 8-fold, whereas carbonylation increased ~1.5-fold in forskolin-treated BeWoA cells.

Because oxidative stress is the basis of nitrosative stress when NO is present (from arginine being changed to citrulline + NO by nitric oxide synthase), we analyzed the expression of the inducible nitric oxide





**Figure 8. Analysis of Membrane Repair in Trophoblast Cells Overexpressing either Isoform of STOX1**

(A) Western blot analysis of six annexins and quantification (left). Data are mean  $\pm$  SEM from three experiments. Video microscopy analysis of FM1-43 kinetics entering the cell from the point of laser-generated injury.

(B) Fluorophore entry kinetics in JEG-3 EVT. Quantification is presented in Figure 7F where JEG-3C cells are JEG-3 cells stably transfected with a geneticin resistance plasmid and JEG-3A cells stably overexpress STOX1A. In these cells, the membrane repair does not occur whatever the level of STOX1A.

(C) BeWoC cells kinetic of membrane repair (BeWo cells stably expressing the geneticin resistance gene), quantified in Figures 8F and 8G.

(D and E) (D) BeWoA cells (with overexpression of STOX1A) kinetic of membrane repair and (E) BeWo cells (overexpressing STOX1B). (F and G) quantification of the intracellular fluorescence in trophoblast cells; JEG3C are control JEG-3 trophoblast cells, JEG3A are JEG-3 cells overexpressing STOX1A. BeWo and BeWoC are control BeWo cells, while BeWoA and BeWoB overexpress STOX1A and STOX1B, respectively.

(H) Video microscopy of the fluorescence entry in BeWoA cells, as an example (similar images were obtained with BeWoB cells). At 6.5 and 7.8 s post-injury, the blue arrows show the extrusion of cytoplasmic material. At 52 s, intracellular vesicles are formed but are not able to fuse and not able to patch the cell membrane. Scale bar: 20  $\mu$ m for figures B–E, 5  $\mu$ m for Figure (H). In all the figures, the lesion point is indicated by the white arrow.

synthase, NOS3. In DMSO-treated cells, BeWoA cells presented a ~45% reduced level of the NOS3 protein compared with control BeWoC cells, whereas the mRNA level was unchanged (Figure 10B). When the cells were induced to fuse, the increase in NOS3 mRNA was around 30-fold in BeWoA cells exclusively, and this translated into a 4-fold induction of the protein in forskolin-treated cells. In BeWoB and BeWoC cells, the NOS3 level was also increased following treatment with forskolin but only by ~2-fold. Therefore, in BeWoA cells, forskolin treatment tended to alleviate the oxidative stress increase but to increase NOS3 level. We evaluated the level of nitrosylated proteins in the forskolin-stimulated cells by dot-blot with serial dilutions (Figure 10B, box right), and consistently, the level of nitrosylation was 2- to 3-fold more elevated in BeWoA than in the two other cell lines.


Overall, these results are different to what we previously described in JEG-3 cells overexpressing STOX1A, where we found a decrease in nitrosative stress at atmospheric O<sub>2</sub> pressure, 20% (Doridot et al., 2014). However, at 2% O<sub>2</sub>, the nitrosative stress was increased. This suggests that when STOX1A is overexpressed, BeWo cells at atmospheric oxygen pressure resemble JEG-3 cells in hypoxia in terms of nitrosative stress.

In addition, we studied the level of caveolin 1 in the BeWo cell lines, because this protein is known to protect against oxidative stress, hypoxia, and inflammation (Pavlidis et al., 2010; Shioto et al., 2014). In baseline conditions, overexpression of STOX1B led to a very low protein level, whereas this level was similar in BeWoA and BeWoC cells (Figure 10C). When cells were treated with forskolin, the CAV1 mRNA level was increased in BeWoC and BeWoB but not in BeWoA, whereas the protein level appeared similar in the three cell lines (Figure 10C). This suggests that before fusion, BeWoB cells lack caveolin. Caveolin1 has also been reported to play an important role in cytotrophoblast fusion (Rashid-Doubell et al., 2007). The very low level of this factor in BeWoB cells may suggest an impairment of their capability to fuse, consistently with the observation of altered cell fusion in BeWoB cells.

In sum, our results indicate (1) that STOX1A overexpression leads to different effects on oxidative and nitrosative stresses and (2) that the balance between STOX1A and STOX1B is major for understanding the mode of action of STOX1 in terms of oxidative stress.

## DISCUSSION


We previously showed that STOX1A overexpression in the JEG-3 extravillous trophoblast cell model, leads to an expression profile that mimics that of preeclampsia and induces preeclampsia and intrauterine growth restriction in mouse transgenic models (Collinot et al., 2018; Doridot et al., 2013; Ducat et al., 2016). Trophoblast cell lines overexpressing STOX1 isoforms could therefore be a useful scientific resource to understand some of the cellular and molecular grounds of placental diseases. STOX1 was first described as a transcription factor, of which specific variants predispose to preeclampsia (van Dijk et al., 2005). The gene is encountered under two major isoforms, STOX1A (989 amino acids) and STOX1B (227 amino acids), which share the same DNA binding site(s). The two isoforms differ by the existence of a transactivating domain exclusive to STOX1A, and shuttling nucleus-cytoplasm signals (NLS and NES), whereas STOX1B encompasses only an NLS together with the DNA-binding domain. The binding site of STOX1 was not described before the present study. Herein, we identified by PCR-selection two putative regulatory DNA elements (STRE1 and STRE2), one of which (STRE1) is specifically



**Figure 9. Altered Fusion Consequences and Molecular Mechanisms with Overexpression of STOX1 Isoforms**

(A) Syncytin gene deregulations. In BeWoA, B, and C cells (blue, orange, and gray boxes, respectively), the ratio between the mRNA levels of these genes under forskolin treatment relative to control treatment (DMSO) is shown (results presented following a logarithmic scale).

(B–D) (B) Expression of the genes encoding the beta chain of the hCG under fusion induced by forskolin treatment in BeWoA, BeWoB, and BeWoC cells. xCELLigence analysis of the impedance of the different BeWo cell lines without (C) and with (D) forskolin treatment. Error bars at each measure (every 15 min) are from the analysis of triplicates. Under forskolin treatment the fusion starts after 9 h of culture (blue arrow). Data (C and D) are mean  $\pm$  SEM from three experiments.



**Figure 10. Analysis of the Modulation of Oxidative/Nitrosative Stress Markers in BeWo Cells Overexpressing STOX1 Isoforms**

(A) Western blot analysis of the impact of oxidative stress (carbonylated proteins) in BeWo cells stably transfected to overexpress STOX1A (BeWoA) or STOX1B (BeWoB) and control cells (BeWoC), with or without syncytialization induction by forskolin (FSK) treatment. Quantification relative to tubulin B level, as described in (Doridot et al., 2014).

**Figure 10. Continued**

(B) Quantification by qRT-PCR (left) and Western blot analysis (right) of eNOS normalized by protein content (evaluated at 20  $\mu$ g per lane before the loading by Bradford test,  $n = 3$ ). In the more extreme frame is represented the global level of nitrosylated proteins evaluated by dot-blot serial dilution analysis for BeWo cells treated with Forskolin.

(C) Caveolin content analyzed as eNOS content. Data on WB quantification and on qRT-PCR graphs are mean  $\pm$  SEM from three experiments.

bound by STOX1. We surmise that STRE2 can bind a cofactor of STOX1, thus allowing STOX1 to perform its action; identifying this factor is the subject of ongoing studies. We also generated complementary cell models stably overexpressing either of STOX1 variants in the BeWo villous cytotrophoblast. These tools allowed us to attempt elucidating how STOX1 intervenes to modulate gene expression. The core STRE1+STRE2 was significantly induced by STOX1A but not by STOX1B in cell transfection experiments. The level of induction was relatively low, suggesting that in actual cellular conditions, the environment of the sites is crucial to enhance the effect of STOX1 isoforms on promoters. This could possibly be linked to local DNA methylation levels, as seen for STOX1-mediated regulation of the *HMGN1* promoter.

Besides, we found that in cells, some genes such as *ANXA1* or *HMGN1*, are downregulated by both isoforms of STOX1 in BeWo cells, whereas others such as those involved in syncytialisation (*Syncytins*, *CGB*) were upregulated by STOX1A and downregulated by STOX1B, when the fusion was activated by forskolin treatment. Some other genes, such as those involved in oxidative/nitrosative stress regulations, were generally modified essentially following STOX1A overexpression, toward the overproduction of ROS and RNS. The downregulation of *ANXA1* is a logical culprit for interpreting the failure of membrane repair observed in BeWoA and BeWoB cells. It is known from the analysis of muscle cells that AnnexinA1 is a crucial component of the membrane repair machinery (Lennon et al., 2003). Our results strongly suggest that STOX1A or STOX1B overexpression leads to a virtual invalidation of the *ANXA1* gene and completely prevents membrane repair in BeWo cells. In terms of trophoblast physiology, the fact that only the villous cell line was able to repair their membranes is consistent with the fact that villous cells differentiate into syncytiotrophoblast that are exposed directly to the blood flow and need presumably to be repairable for an optimal placental function. To this respect, JEG-3 cells behave probably more like extravillous trophoblasts that proliferate, suggesting that the absence of membrane repair that could lead to cell death is less important in this type of cells.

In sum, although downregulation of STOX1 does not affect strongly gene expression in the placental cells, imbalance between the two isoforms of STOX1 (generated by selective overexpression of each) leads to hindrances of pathways that are vital for not only trophoblast/placental function, such as membrane repair, cell-cell fusion, a major issue in placental physiology in mammalian and even non-mammalian viviparous placental species (Cornelis et al., 2015, 2017; Dupressoir et al., 2005), but also the management of molecules involved in oxidative/nitrosative stress. This oxidative-nitrosative stress balance is a major issue in the pathogenesis of preeclampsia (Amaral et al., 2013; Aouache et al., 2018; Saenen et al., 2017; Taysi et al., 2019). This observation could suggest that if an invalidation experiment of STOX1 in mice was carried out, no strong placental phenotype would be expected. However, introducing either STOX1A or STOX1B in this genetic background could have devastating effects on placental function, consistently with the overexpression of STOX1A in mice that induced preeclamptic symptoms (Doridot et al., 2013).

Overall, our present observations substantiate a previous hypothesis that we proposed (Vaiman and Miralles, 2016), envisaging that the imbalance between the two STOX1 major isoforms is a driving force toward abnormal placental function.

In 2011, van Abel and coworkers performed a ChIP-seq experiment using a human neuroblastoma cell line (SK-N-SH) overexpressing STOX1A, which made it possible to identifying STOX1 targets (van Abel et al., 2011). Among those, 76 were in the vicinity of genes that could be compared with the BeWo and JEG microarrays that we performed herein and in previous experiments. Analyzing by  $\chi^2$  the proportion of deregulated genes from our own microarray data, we did not find significant expression biases in the genes nearby the sequences enriched during the ChIP-seq experiment (data not shown). Therefore, either the binding had no statistically detectable influence on the gene expression (concerning a too limited number of direct targets of STOX proteins) or the binding/gene expression regulation is quite different according to the cell model that was used.

Our results also demonstrate that STOX1 acts pleiotropically on the trophoblast wellbeing, through a harmonious balance between its two DNA-binding isoforms. Recently, we showed that alternative splicing

of *STOX1* occurs differently in preeclamptic versus control placentas samples (Figure S1), suggesting that the balance between the two *STOX1* isoform could indeed be a relevant mechanism of placental pathogenesis. Intuitively, when two isoforms of the same transcription factor share the same DNA-binding domain, the existence of a competition between them can be expected. Such regulation has rarely been described but has been previously documented for *FOXJ2* (Perez-Sanchez et al., 2000). Similarly, the chromodomain helicase *CHD7* presents a transcript variant that has opposite regulatory effects through binding *SOX2* in the nucleoplasm, the long isoform (*CHD7L*) promoting *SOX2*-mediated transcriptional regulation while the short isoform (*CHD7S*) suppressing it (Kita et al., 2012).

One of the limits of our models is the use of choriocarcinoma, which may differ from primary cells. However, these cells are widely used to modelize placental cells, and this is supported by a very abundant literature, with results generally very relevant for understanding actual placental function. Another putative limit is the fact that we tilt the balance between *STOX1A* and *STOX1B* through overexpression of each isoform, rather than selective suppression of one of them. This solution is nevertheless handier and closer to the actual *in vivo* situation, than to eliminate selectively each isoform; the overexpression that we detect is ~5–~20 times above the basal level, a concentration that will improbably lead to non-specific binding to promoter elements. Indeed, compared with a ubiquitous factor such as *RNAPol2*, the basal expression level of *STOX1* is ~58-fold inferior (microarray data).

Recently, the idea of reproducing the feto-maternal interface was envisaged with cell models of co-culture of JEG-3, BeWo, and syncytialized BeWo cells together with the adrenal H295R cell line (Drwal et al., 2018). Mimicking the normal interface is interesting, but in the future, using our cell models we could be able to model this interface in a disease state, such as preeclampsia. By *STOX1* overexpression, we mimic the status of VCT and EVT cells in preeclampsia. Future effort, fostering on our results on *STOX1*-induced modification of trophoblast function, could therefore be endeavored to provide a cell-based model of the preeclamptic placenta. Also, recent studies mentioned the possibility of generating organoids from trophoblasts (Turco et al., 2018). In this model, transfection of *STOX1A* or *STOX1B* using a lentivirus could help to better understand the action of this factor in the context of the preeclamptic disease, in a model closer to actual placental tissue.

### Limitations of the Study

This study is based upon cell models, essentially on BeWo cells, which are a good model of villous trophoblast, but still only a model. Although they are very useful to explore mechanistical questions, the behavior of primary trophoblast cells they represent is not completely accurate and even less that of the whole placenta, which includes a high proportion of mesenchymal end endothelial, as well as immunologic cells. Another limit is the luciferase assays that could be carried out on additional cell lines to see the generality of the behavior that we observed. Thirdly, the results on *HMG1* indicate that genome methylation could play an important role in modulating *STOX1* response. This could be studied thoroughly at the genome level using methylation arrays such as EPIC (Illumina) to obtain a more comprehensive vision of gene regulation by *STOX1*. The same remarks could be done for the study of the chromatin status that could be approached thoroughly by ChIP-seq, an issue that was beyond the scope of the present study.

### METHODS

All methods can be found in the accompanying [Transparent Methods supplemental file](#).

### DATA AND CODE AVAILABILITY

The BeWo array was deposited at GEO profiles under the accession number GSE148088. If readers wish to have access to the modified cells presented here, they can contact the authors that will share their material.

### SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at <https://doi.org/10.1016/j.isci.2020.101086>.

### ACKNOWLEDGMENTS

The authors thank the team of the Genom'IC platform of the Cochin Institute, especially Angéline Duche, and Franck Letourneur for the quality or their services. This work was funded by the recurrent dotation of Inserm/CNRS/University attributed to the teams. Funding of AD PhD was through the Paris-Descartes

doctoral school. The PhD projects of CRSM and CA is funded by the European Union's Horizon 2020 research and innovation programme under Marie Skłodowska-Curie Actions Innovative Training Network (H2020-MSCA-ITN 2017), Grant No. 765274, acronym iPLACENTA (<http://www.iplacenta.eu>). PL had his salary paid by BIOPAS Laboratories for working in projects different to that described in the present manuscript. Christel Poujol and Sébastien Marais are acknowledged for the help in membrane repair assays that were done in the Bordeaux Imaging Center, a service unit of the CNRS-INSERM and Bordeaux University, member of the national infrastructure France Biolmaging supported by the French National Research Agency (ANR-10-INBS-04).

## AUTHOR CONTRIBUTIONS

AD, BC, LD, IG, AJ, and DV were the main actors of the identification of the STOX1 binding site and of the generation of the BeWoA, B, and C cell lines. RNA extractions and RT-qPCR were performed by RA, LB, and DV. Knock-down of STOX1 was carried out by DV. Luciferase assays were performed by SP, YC, and AV. Western blot analysis was carried out by LB and RA. Gel-shift assays were the work of AD, IG, AJ, and DV. The membrane repair analysis was carried out by AB and LF. The fusion analysis of the BeWo cells was performed by MBC and PR. The mouse placentas, transgenic or not, were provided from BP and JLV. Methylation analyses were performed by JT and FB. Transcriptome assays were carried out by SJ. Monitoring of proliferation by xCELLigence was carried out by CA. Bioinformatics analysis was supervised by DV and carried out by FM, with the help of JC and CRSM. The drafting of the paper was carried out by DV, CM, PL, JC, and DV. The project was managed by DV.

## DECLARATION OF INTERESTS

None.

Received: November 5, 2019

Revised: March 16, 2020

Accepted: April 15, 2020

Published: May 22, 2020

## REFERENCES

- Abel, D., Abdul-Hamid, O., Dijk, M., and Oudejans, C.B. (2012). Transcription factor STOX1A promotes mitotic entry by binding to the CENB1 promoter. *PLoS One* **7**, e29769.
- Amaral, L.M., Pinheiro, L.C., Guimaraes, D.A., Palei, A.C., Sertorio, J.T., Portella, R.L., and Tanus-Santos, J.E. (2013). Antihypertensive effects of inducible nitric oxide synthase inhibition in experimental pre-eclampsia. *J. Cell. Mol. Med.* **17**, 1300–1307.
- Aouache, R., Biquard, L., Vaiman, D., and Miralles, F. (2018). Oxidative stress in preeclampsia and placental diseases. *Int. J. Mol. Sci.* **19**, 1496.
- Azar, C., Valentine, M., Trausch-Azar, J., Druley, T., Nelson, D.M., and Schwartz, A.L. (2018). RNA-Seq identifies genes whose proteins are transformative in the differentiation of cytotrophoblast to syncytiotrophoblast, in human primary villous and BeWo trophoblasts. *Sci. Rep.* **8**, 5142.
- Bailey, T.L., Boden, M., Buske, F.A., Frith, M., Grant, C.E., Clementi, L., Ren, J., Li, W.W., and Noble, W.S. (2009). MEME SUITE: tools for motif discovery and searching. *Nucleic Acids Res.* **37**, W202–W208.
- Bouter, A., Gounou, C., Berat, R., Tan, S., Gallois, B., Granier, T., d'Estaintot, B.L., Poschl, E., Brachvogel, B., and Brisson, A.R. (2011). Annexin-A5 assembled into two-dimensional arrays promotes cell membrane repair. *Nat. Commun.* **2**, 270.
- Boye, T.L., and Nylandsted, J. (2016). Annexins in plasma membrane repair. *Biol. Chem.* **397**, 961–969.
- Carbillon, L., Challier, J.C., Alouini, S., Uzan, M., and Uzan, S. (2001). Uteroplacental circulation development: Doppler assessment and clinical importance. *Placenta* **22**, 795–799.
- Carmeille, R., Degrelle, S.A., Plawinski, L., Bouvet, F., Gounou, C., Evain-Brion, D., Brisson, A.R., and Bouter, A. (2015). Annexin-A5 promotes membrane resealing in human trophoblasts. *Biochim. Biophys. Acta* **1853**, 2033–2044.
- Carmeille, R., Croissant, C., Bouvet, F., and Bouter, A. (2017). Membrane repair assay for human skeletal muscle cells. *Methods Mol. Biol.* **1668**, 195–207.
- Chen, J.Z., Sheehan, P.M., Brennecke, S.P., and Keogh, R.J. (2012). Vessel remodelling, pregnancy hormones and extravillous trophoblast function. *Mol. Cell. Endocrinol.* **349**, 138–144.
- Chirn, G.W., Rahman, R., Sytnikova, Y.A., Matts, J.A., Zeng, M., Gerlach, D., Yu, M., Berger, B., Naramura, M., Kile, B.T., et al. (2015). Conserved piRNA expression from a distinct Set of piRNA cluster Loci in eutherian mammals. *PLoS Genet.* **11**, e1005652.
- Collinot, H., Marchiol, C., Lagoutte, I., Lager, F., Siauve, N., Autret, G., Balvay, D., Renault, G., Salomon, L.J., and Vaiman, D. (2018). Preeclampsia induced by STOX1 overexpression in mice induces intrauterine growth restriction, abnormal ultrasonography and BOLD MRI signatures. *J. Hypertens.* **36**, 1399–1406.
- Cornelis, G., Vernochet, C., Carradec, Q., Souquere, S., Mulot, B., Catzeflis, F., Nilsson, M.A., Menzies, B.R., Renfree, M.B., Pierron, G., et al. (2015). Retroviral envelope gene captures and syncytin exaptation for placentation in marsupials. *Proc. Natl. Acad. Sci. U S A* **112**, E487–E496.
- Cornelis, G., Funk, M., Vernochet, C., Leal, F., Tarazona, O.A., Meurice, G., Heidmann, O., Dupressoir, A., Miralles, A., Ramirez-Pinilla, M.P., et al. (2017). An endogenous retroviral envelope syncytin and its cognate receptor identified in the viviparous placental Mabuya lizard. *Proc. Natl. Acad. Sci. U S A* **114**, E10991–E11000.
- Doridot, L., Passet, B., Mehats, C., Rigourd, V., Barbaux, S., Ducat, A., Mondon, F., Vilotte, M., Castille, J., Breuille-Fouche, M., et al. (2013). Preeclampsia-like symptoms induced in mice by fetoplacental expression of STOX1 are reversed by aspirin treatment. *Hypertension* **61**, 662–668.
- Doridot, L., Chatre, L., Ducat, A., Vilotte, J.L., Lombes, A., Mehats, C., Barbaux, S., Calicchio, R., Ricchetti, M., and Vaiman, D. (2014). Nitroso-redox balance and mitochondrial homeostasis

are regulated by STOX1, a pre-eclampsia-associated gene. *Antioxid.Redox Signal.* 21, 819–834.

Drwal, E., Rak, A., and Gregoraszczyk, E. (2018). Co-culture of JEG-3, BeWo and syncBeWo cell lines with adrenal H295R cell line: an alternative model for examining endocrine and metabolic properties of the fetoplacental unit. *Cytotechnology* 70, 285–297.

Ducat, A., Doridot, L., Calicchio, R., Mehats, C., Vilotte, J.L., Castille, J., Barbaux, S., Couderc, B., Jacques, S., Letourneur, F., et al. (2016). Endothelial cell dysfunction and cardiac hypertrophy in the STOX1 model of preeclampsia. *Sci. Rep.* 6, 19196.

Dupressoir, A., Marceau, G., Vernochet, C., Benit, L., Kanellopoulos, C., Sapin, V., and Heidmann, T. (2005). Syncytin-A and syncytin-B, two fusogenic placenta-specific murine envelope genes of retroviral origin conserved in Muridae. *Proc. Natl. Acad. Sci. U S A* 102, 725–730.

Joubert, B.R., Felix, J.F., Yousefi, P., Bakulski, K.M., Just, A.C., Breton, C., Reese, S.E., Markunas, C.A., Richmond, R.C., Xu, C.J., et al. (2016). DNA methylation in newborns and maternal smoking in pregnancy: genome-wide consortium meta-analysis. *Am. J. Hum.Genet.* 98, 680–696.

Kita, Y., Nishiyama, M., and Nakayama, K.I. (2012). Identification of CHD7S as a novel splicing variant of CHD7 with functions similar and antagonistic to those of the full-length CHD7L. *Genes Cells* 17, 536–547.

Lennon, N.J., Kho, A., Bacskai, B.J., Perlmutter, S.L., Hyman, B.T., and Brown, R.H., Jr. (2003). Dysferlin interacts with annexins A1 and A2 and mediates sarcolemmal wound-healing. *J. Biol. Chem.* 278, 50466–50473.

Mallet, F., Bouton, O., Prudhomme, S., Cheynet, V., Oriol, G., Bonnaud, B., Lucotte, G., Duret, L., and Mandrand, B. (2004). The endogenous retroviral locus ERVWE1 is a bona fide gene involved in hominoid placental physiology. *Proc. Natl. Acad. Sci. U S A* 101, 1731–1736.

Morrish, D.W., Dakour, J., and Li, H. (1998). Functional regulation of human trophoblast differentiation. *J. Reprod.Immunol.* 39, 179–195.

Nie, X., Zhang, K., Wang, L., Ou, G., Zhu, H., and Gao, W.Q. (2015). Transcription factor STOX1 regulates proliferation of inner ear epithelial cells via the AKT pathway. *Cell Prolif.* 48, 209–220.

Omata, W., Ackerman, W.E.t., Vandre, D.D., and Robinson, J.M. (2013). Trophoblast cell fusion and differentiation are mediated by both the protein kinase C and a pathways. *PLoS One* 8, e81003.

Orendi, K., Gauster, M., Moser, G., Meiri, H., and Huppertz, B. (2010). Effects of vitamins C and E, acetylsalicylic acid and heparin on fusion, beta-hCG and PP13 expression in BeWo cells. *Placenta* 31, 431–438.

Pantham, P., Rosario, R., Chen, Q., Print, C.G., and Chamley, L.W. (2012). Transcriptomic analysis of placenta affected by antiphospholipid

antibodies: following the TRAIL of trophoblast death. *J. Reprod.Immunol.* 94, 151–154.

Pavlidis, S., Tsigirgos, A., Vera, I., Flomenberg, N., Frank, P.G., Casimiro, M.C., Wang, C., Fortina, P., Addya, S., Pestell, R.G., et al. (2010). Loss of stromal caveolin-1 leads to oxidative stress, mimics hypoxia and drives inflammation in the tumor microenvironment, conferring the "reverse Warburg effect": a transcriptional informatics analysis with validation. *Cell Cycle* 9, 2201–2219.

Perez-Sanchez, C., Gomez-Ferrera, M.A., de La Fuente, C.A., Granadino, B., Velasco, G., Esteban-Gamboa, A., and Rey-Campos, J. (2000). FHx, a novel fork head factor with a dual DNA binding specificity. *J. Biol. Chem.* 275, 12909–12916.

Pidoux, G., Gerbaud, P., Cocquebert, M., Segond, N., Badet, J., Fournier, T., Guibourdenche, J., and Evain-Brion, D. (2012). Review: human trophoblast fusion and differentiation: lessons from trisomy 21 placenta. *Placenta* 33 (Suppl), S81–S86.

Pollock, R.M. (20). Determination of protein-DNA sequence specificity by PCR-assisted binding-site selection. *Curr. Protoc. Mol. Biol.*, Chapter 12, Unit 12.11.

Rashid-Doubell, F., Tannetta, D., Redman, C.W., Sargent, I.L., Boyd, C.A., and Linton, E.A. (2007). Caveolin-1 and lipid rafts in confluent BeWo trophoblasts: evidence for Rock-1 association with caveolin-1. *Placenta* 28, 139–151.

Rigourd, V., Chauvet, C., Chelbi, S.T., Rebourcet, R., Mondon, F., Letourneur, F., Mignot, T.M., Barbaux, S., and Vaiman, D. (2008). STOX1 overexpression in choriocarcinoma cells mimics transcriptional alterations observed in preeclamptic placentas. *PLoS One* 3, e3905.

Robinson, N.J., Baker, P.N., Jones, C.J., and Aplin, J.D. (2007). A role for tissue transglutaminase in stabilization of membrane-cytoskeletal particles shed from the human placenta. *Biol. Reprod.* 77, 648–657.

Ruttkey-Nedecky, B., Nejdil, L., Gumulec, J., Zitka, O., Masarik, M., Eckschlager, T., Stiborova, M., Adam, V., and Kizek, R. (2013). The role of metallothionein in oxidative stress. *Int. J. Mol. Sci.* 14, 6044–6066.

Saenen, N.D., Vrijens, K., Janssen, B.G., Roels, H.A., Neven, K.Y., Vanden Berghe, W., Gyselaers, W., Vanpoucke, C., Lefebvre, W., De Boever, P., et al. (2017). Lower placental leptin promoter methylation in association with fine particulate matter air pollution during pregnancy and placental nitrosative stress at birth in the ENVIRONMENT cohort. *Environ.Health Perspect.* 125, 262–268.

Shankar, K., Kang, P., Zhong, Y., Borengasser, S.J., Wingfield, C., Saben, J., Gomez-Acevedo, H., and Thakali, K.M. (2015). Transcriptomic and epigenomic landscapes during cell fusion in BeWo trophoblast cells. *Placenta* 36, 1342–1351.

Shioto, T., Romero, N., Sugiyama, T., Sartoretto, J.L., Kalwa, H., Yan, Z., Shimokawa, H., and Michel, T. (2014). Caveolin-1 is a critical

determinant of autophagy, metabolic switching, and oxidative stress in vascular endothelium. *PLoS One* 9, e87871.

Szklarczyk, D., Gable, A.L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., Simonovic, M., Doncheva, N.T., Morris, J.H., Bork, P., et al. (2019). STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res.* 47, D607–D613.

Taysi, S., Tascan, A.S., Uuro, M.G., and Demir, M. (2019). Radicals, oxidative/nitrosative stress and preeclampsia. *Mini Rev. Med. Chem.* 19, 178–193.

Turco, M.Y., Gardner, L., Kay, R.G., Hamilton, R.S., Prater, M., Hollinshead, M.S., McWhinnie, A., Esposito, L., Fernando, R., Skelton, H., et al. (2018). Trophoblast organoids as a model for maternal-fetal interactions during human placentation. *Nature* 564, 263–267.

Tyberghein, K., Goossens, S., Haigh, J.J., van Roy, F., and van Hengel, J. (2012). Tissue-wide overexpression of alpha-T-catenin results in aberrant trophoblast invasion but does not cause embryonic mortality in mice. *Placenta* 33, 554–560.

Vaiman, D., and Miralles, F. (2016). Targeting STOX1 in the therapy of preeclampsia. *Expert Opin.Ther. Targets* 20, 1433–1443.

van Abel, D., Holzel, D.R., Jain, S., Lun, F.M., Zheng, Y.W., Chen, E.Z., Sun, H., Chiu, R.W., Lo, Y.M., van Dijk, M., et al. (2011). SFRS7-mediated splicing of tau exon 10 is directly regulated by STOX1A in glial cells. *PLoS One* 6, e21994.

van Abel, D., Abdulhamid, O., Scheper, W., van Dijk, M., and Oudejans, C.B. (2012a). STOX1A induces phosphorylation of tau proteins at epitopes hyperphosphorylated in Alzheimer's disease. *Neurosci.Lett.* 528, 104–109.

van Abel, D., Michel, O., Veerhuis, R., Jacobs, M., van Dijk, M., and Oudejans, C.B. (2012b). Direct downregulation of CNTNAP2 by STOX1A is associated with Alzheimer's disease. *J. Alzheimers Dis.* 31, 793–800.

van Dijk, M., Mulders, J., Poutsma, A., Konst, A.A., Lachmeijer, A.M., Dekker, G.A., Blankenstein, M.A., and Oudejans, C.B. (2005). Maternal segregation of the Dutch preeclampsia locus at 10q22 with a new member of the winged helix gene family. *Nat. Genet.* 37, 514–519.

van Dijk, M., van Bezu, J., van Abel, D., Dunk, C., Blankenstein, M.A., Oudejans, C.B., and Lye, S.J. (2010). The STOX1 genotype associated with preeclampsia leads to a reduction of trophoblast invasion by alpha-T-catenin upregulation. *Hum. Mol. Genet.* 19, 2658–2667.

Zhang, C., Ji, Z., Wang, M., Zhang, W., Yang, R., An, H., Yang, R., van Abel, D., van Dijk, M., Yang, X., et al. (2016). Stox1 as a novel transcriptional suppressor of Math1 during cerebellar granule neurogenesis and medulloblastoma formation. *Cell Death Differ.* 23, 2042–2053.

## **Supplemental Information**

### **Molecular Mechanisms of Trophoblast**


#### **Dysfunction Mediated by Imbalance**

#### **between STOX1 Isoforms**


**Aurélien Ducat, Betty Couderc, Anthony Bouter, Louise Biquard, Rajaa Aouache, Bruno Passet, Ludivine Doridot, Marie-Benoîte Cohen, Pascale Ribaux, Clara Apicella, Irène Gaillard, Sophia Palfray, Yulian Chen, Alexandra Vargas, Amélie Julé, Léo Frelin, Julie Cocquet, Camino Ruano San Martin, Sébastien Jacques, Florence Busato, Jorg Tost, Céline Méhats, Paul Laissue, Jean-Luc Vilotte, Francisco Miralles, and Daniel Vaiman**



11 PE vs 9 controls: Splicing index 1.36,  $p=0.0123$




13 IUGR vs 8 controls: Splicing index 1.11,  $p=0.3262$



Signal 5 8


**Supplementary Figure S1, Structure of STOX1 major isoforms STOX1A and STOX1Bn and splicing index in preeclampsia (PE) versus controls and in Intra-Uterine Growth Restriction (IUGR) versus controls, Related to Figure 2b and paragraph 6 of the Discussion in the main text. The p values were provided following TAC® Affymetrix software analysis from ClariomD microarrays (manuscript in preparation)**

Construction STRE21F	GCTATGGTGYGGAMAGCGCCATYTCACGGAGATGGTGYGGAMAGCGCCATYTCACGGAGAGGC	
Construction STRE21R	GCTCTCCGTGARATGGCGCTKTCRCACCATCTCCGTGARATGGCGCTKTCRCACCATAGC	
Construction mSTRE21F	GCTATGATGYTGAMAGCGCCACYTCATGGAGATGATGYTGAMAGCGCCACYTCATGGAGAGGC	
Construction mSTRE21R	GCTCTCCATGARGTGGCGCTKTCARCATCATCTCCATGARGTGGCGCTKTCARCATCATAGC	



**Supplementary Figure S2, Luciferase constructions with normal and mutant STRE elements (Related to Figure 1):** upper part, presentation of the constructions encompassing WT and mutant variants of STRE1 and STRE2. Lower part, luciferase assays analyzing the constructions by transfections in JEG3 cells (related to Figure 1). Tested by Student T-tests compared to control conditions \*\*  $p < 0.01$ .

## Cell Fusion quantification ANOVA $p < 0.0001$



**Supplementary Figure S3, Visual evaluation of cell fusion in BeWo cells overexpressing either STOX1A or STOX1B (Related to Figure 9).** P values were calculated by Student Neuman Keuls pos-hoc test after one-way ANOVA (pool of three independent experiments).

Supplementary Table S1: qPCR oligonucleotides used in the study. Related to Figure 1.

Oligo name	Sequence	Bases
ANXA1.f	GCG-GTG-AGC-CCC-TAT-CCT-A	19
ANXA1.r	TGA-TGG-TTG-CTT-CAT-CCA-CAC	21
ANXA2.f	TCT-ACT-GTT-CAC-GAA-ATC-CTG-TG	23
ANXA2.r	AGT-ATA-GGC-TTT-GAC-AGA-CCC-AT	23
BRWD1.f	CCA-GCG-CAT-CGG-TCC-TAT-G	19
BRWD1.r	CTT-CCT-GCA-CCA-AGT-AAA-GAA-GT	23
CAPN6.f	CAG-CAG-ACT-TTT-CTG-TGA-TCC-A	22
CAPN6.r	GGG-GAC-GTT-TCC-ACA-CCA-C	19
GPR146.f	GCA-AGG-CCA-GCA-TGA-CCA-T	19
GPR146.r	GGA-CAC-ATT-GAA-GGG-GAT-CTG	21
HMGN1.f	GCG-AAG-CCG-AAA-AAG-GCA-G	19
HMGN1.r	TCC-GCA-GGT-AAG-TCT-TCT-TTA-GT	23
ITIH5.f	CCT-ACT-GTA-GTA-CAA-CAA-GCC-AG	23
ITIH5.r	TCC-CCA-ATG-CTC-TGT-TCT-CTA-TT	23
PSMG1.f	TCC-TTT-CCT-GAG-AGC-CCT-AAA-A	22
PSMG1.r	TGT-TCT-AGC-AAT-GGA-CAA-CAC-G	22
SEMA6A.f	AAT-CAG-TAT-TTC-GCA-TGG-CAA-CT	23
SEMA6A.r	GCA-ATG-TAG-AGG-GTT-CCG-TTC-A	22
TGM2.f	CGT-GAC-CAA-CTA-CAA-CTC-GG	20
TGM2.r	CAT-CCA-CGA-CTC-CAC-CCA-G	19
WRB.f	TCC-ACA-GTC-AAC-ATG-ATG-GAC-G	22
WRB.r	CTG-TCC-GAG-CTT-TCA-CAT-GGG	21
ERVFRD-1_(Syncytin1.f)	ATG-GAG-CCC-AAG-ATG-CAG	18
ERVFRD-1_(Syncytin1.r)	AGA-TCG-TGG-GCT-AGC-AG	17
ERVW-1_(Syncytin2.f)	CCT-TCA-CTA-GCA-GCC-TAC-CG	20
ERVW-1_(Syncytin2.r)	GCT-GTC-CCT-GGT-GTT-TCA-GT	20
CGA.f	TGC-CCA-GAA-TGC-ACG-CTA-C	19
CGA.r	TTG-GAC-CTT-AGT-GGA-GTG-GGA	21
NOS3.f	TGA-TGG-CGA-AGC-GAG-TGA-AG	20
NOS3.r	ACT-CAT-CCA-TAC-ACA-GGA-CCC	21
CAV1.f	GCG-ACC-CTA-AAC-ACC-TCA-AC	20
CAV1.r	ATG-CCG-TCA-AAA-CTG-TGT-GTC	21

## Transparent Methods

### 1. Human and animal material

Human placental samples previously obtained after Caesarean section outside of labour. Placentas were collected less than half an hour after delivery, two cotyledons were dissected and washed in sterile PBS after removal of the fetal membranes (GascoinLachambre et al., 2010). Several samples of villous trees were placed in Trizol™ prior to RNA extraction. The placentas were collected from four hospital maternity units (Cochin, St Antoine, Institut de Puériculture, Paris, and La Conception, Marseille, France). All protocols have been approved by the local Ethics Committee (No. CPP Am5724-1-COL2991; CODECOH No. DC-2012-1645). All patients have given their written consent for the use of their placenta. The mouse work (female mice, of course) was performed under the local regulations and ethic committees: Animal Care Committee of the Paris Descartes University (agreement no. 02731.02). Placentas were collected at 16.5 days post coitum and placed in TriZol prior to RNA extraction (Collinot et al., 2018; Doridot et al., 2013).

### 2. Cell culture

BeWo cells were cultivated in F12 medium (Life Technologies) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin in 6-cm diameter plates, up to 60% confluence and were transfected by using Lipofectamin 2000 Reagent (Invitrogen) with 4 µg pCMX-STOX1-A, 4 µg pCMX-STOX1-B or 4 µg empty pCMX together with 0.4 µg PGK neo, following the provider's recommendations. Cells were passaged at 1:10 dilution into selective medium at 72 hr post-transfection. Selection was continuously applied with Geneticin (G-418) (Invitrogen) at 500 µg/ml concentration for approximately 3 weeks. Resistant clones were grown individually in continual selection and used for further analysis or frozen in DMSO. mRNA was prepared and the expression of STOX1A or B was assessed by qRT-PCR. Three cell lines were retained and called BeWoA, BeWoB and BeWoC (control cell line). A similar experiment was performed for generating an STOX1B-overexpressing cell from JEG-3 cells (grown in DMEM – 10% FBS – 1% penicillin/streptomycin), to isolate a clone overexpressing STOX1B ~3-fold (as evaluated by qRT-PCR), and called B10 (JEG-3B in this paper). All these cell lines, including AA6 (JEG-3A) and BD3 (JEG-3C) JEG-3 cells as well as other control and STOX1A-overexpressing cells were maintained in selective pressure in geneticin G-418 at 500 µg/ml (Rigourdet et al., 2008). To evaluate cell fusion, BeWo A, B or C cells were seeded in µ-slide 8-well IbiTreat chamber slides (30'000 cells/well; Ibidi GmbH, Martinsried, Germany) 24 hr before treatment with 20 µM forskolin (in medium without G-418) for 48 hr. Cells were then washed with phosphate-buffered saline (PBS) twice, fixed with 4% paraformaldehyde (Aldrich, Steinheim, Germany) for 20 min and washed again with PBS three times. Fixed cells were permeabilized with PBS-0.2% Triton X100 (BioChemica AppliChem, Darmstadt, Germany) for 10 min at room temperature and washed three times with PBS. Non-specific binding was blocked with PBS-3% bovine serum albumin (BSA, Albumin Fraction V, PanReac AppliChem, Barcelona, Spain) for 30 min at room temperature. Cells were then incubated with mouse anti-γ-Catenin antibodies (1:200 dilution from ThermoFisher Scientific, Switzerland) diluted in PBS-3% BSA, overnight at 4°C. Cells were then washed with PBS three times and incubated with goat anti-mouse IgG Chromeo 642 (ab60318, dilution 1:500 from Abcam, Cambridge, UK) diluted in PBS-3% BSA, for 2 hr at room temperature. After three washes with PBS in the dark, cells were incubated with 300 nM DAPI solution (Panreac AppliChem, Barcelona, Spain) for 10 min at room temperature in the dark. Finally, cells were washed three times with PBS in the dark and images were acquired with an EVOS FL Cell Imaging System (ThermoFisher Scientific, Bothell, WA, USA). Images were processed by using ImageJ freeware. The fusion index expressed in percentage was calculated as follows:  $[(N-S)/T] \times 100$ , where N equals the number of nuclei in syncytia, S the number of syncytia and T the total number of nuclei counted.

This index was calculated in three independent experiments, run in duplicate. xCELLIGENCE analysis was performed in triplicate with or without Forskolin with three starting concentrations of cells during 140 hr.

siRNA Knock-down of STOX1 was carried out on BeWo cells using the Mission® esiRNA (Sigma-Aldrich, ref HU-6582-1). Cells from two different experiments were cultivated in 12-well plates and the transfections were carried in 6-plicates, with control or siRNA (at 1nM final concentration), with or without forskolin (24µM final concentration). The siRNA was added to cells (50% confluency) on day1, the forskolin on day2, and the RNA were collected on day 5 in TriZol, using standard protocols.

### 3. Membrane repair assay

JEG-3 and BeWo cells were cultured in complete growth medium complemented with Geneticin at 500 µg/mL on µ-slide 8-well IbiTreat chamber slides (Biovalley). Cells were incubated for 5 min before acquisition with 5 µg/mL FM1-43 (Invitrogen) in D-PBS and maintained over ice. FM1-43 is a water-soluble dye that becomes fluorescent upon integration into lipid membranes but is unable to cross them. When the cell membrane is damaged, the molecule enters passively into the cytosol and incorporates into intracellular membranes, thus increasing the recorded fluorescence. To induce membrane damage, cells were irradiated at 820 nm with a tunable pulsed depletion laser Mai Tai HP (Spectra-Physics, Irvine, CA, USA) with a two-photon confocal scanning microscope (TCS SP5, Leica) equipped with an HCX PL APO CS 63.0 x 1.40 oil-objective lens. Irradiation consisted of 1 scan of a 1 x 1 µm area with power 110 (±5) mW. We acquired 512 x 512 images at 1.6-s intervals with pinhole set to 1 Airy unit. Membrane rupture and repair processes were monitored by measuring variations in fluorescence intensity of FM1-43. FM1-43 was excited by the 488-nm laser line (intensity set at 30% of maximal power) and fluorescence emission was measured between 520 and 650 nm. For each condition, at least 100 cells from three independent experiments were analyzed. For quantitative analysis, the fluorescence intensity was integrated over the whole cell surface and corrected for the fluorescence value recorded before irradiation by using ImageJ (Carmeille et al., 2017; Carmeille et al., 2015).

### 4. High-throughput studies

Microarray analysis on BeWo cell lines were performed with ClariomS human Microarrays (ThermoFisher Scientific) at the Genom'IC platform of Cochin Institute ([https://www.institutcochin.fr/core\\_facilities/genome-sequencing-studies?set\\_language=en](https://www.institutcochin.fr/core_facilities/genome-sequencing-studies?set_language=en)). mRNAs were purified from the three cell lines treated or not with forskolin. The data were submitted to GEO Profiles under the accession number GSE148088, and analyzed using the Transcriptome Analysis Console from Affymetrix (Thermofisher™). P value and FDR values were estimated and are accessible. The genes that are analyzed as modified in the present study have all a FDR-p value <0.05, and are presented as Supplementary Table 1.

### 5. Western blot and Dot-Blot analyses

Cells were trypsinized, pelleted, washed twice in PBS, and resuspended for 1 hr at 4°C in RIPA (5 mM TrisHCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) with a cocktail of protease inhibitors (100X Thermofisher), DTT 50 mM 1%, PMSF 50 mM 1%. Then, after centrifugation (20000 g, 4°C), the supernatant was kept at -70°C after quantification by absorbance evaluation at 280 nm, against a BSA reference scale. Oxidized proteins were measured by using the Oxyblot kit (Merck) following the manufacturer's advice. For eNOS and CAV1, 30 µg denatured proteins (in Nupage LDS sample buffer, Invitrogen, heated 5 min at 100°C) were loaded on 12% (CAV1), 8% (eNOS) or 10% (oxidized proteins) acrylamide-bis acrylamide denaturing gels. Runs were performed at 130 volts for 2 hr in Tris-

Glycine, 2% SDS buffer, at room temperature, then proteins were transferred to nylon or ethanol-activated PVDF membranes at 70 volts in Tris-Glycine buffer at 4°C for 2 hr. The transfer was evaluated by Ponceau red visualization. Membranes were blocked in PBS 1X-Tween 0.1% and 5% defatted milk (Regilait) for 1 hr, then rinsed thrice in PBS 1X-Tween 0.1%. Dot blots were prepared on a grid with serial ½ PBS dilutions by spotting protein extracts on a nitrocellulose gridded membrane.

Antibodies were used at 1 µg/ml (1/1000) for eNOS (BDscience) and 1/500 for caveolin 1 (PA1-064, Thermofisher), and those provided for the Oxyblot kit (Merck, diluted 1/500 in PBS 1%, Tween 0.1% 20% and 5% BSA, 2 µg/ml = 1/500) for nitrated proteins on dot blots (A-21285, Thermofisher). Following incubations and washings, horseradish peroxidase-coupled secondary antibodies were incubated, and signals were revealed by autoradiography, followed by Scion Image or ImageJ analyses for quantification. In the paper, blots were cropped and reorganized for consistency.

## 6. Quantitative RT-PCR

RNA preparation was carried out in cells by direct lysis in Trizol. For tissues, a metal bead was added, and the tissue was homogenized using violent back and forth agitation (1 min, 30 Hz). Chloroform (1/5 of the Trizol volume) was then added to the tube. After centrifugation at 5000g the upper phase (aqueous) was collected in fresh tubes, precipitated with isopropanol; the pellet was resuspended in 100 µl of water, and reprecipitated using 250µl of a NaAc-Etoh mix (300 mM NaAc final). Reverse transcription was carried out using the MMLTV reverse transcriptase kit of Invitrogen (Thermofisher). By using the geometric average of the SDHA and Cyclophilin Cts as a calibrator and the Sybergreen SYBR Hi-ROX qPCR kit from Bioline. cDNA quantity was estimated by the  $2^{-\Delta\Delta C_t}$  method (Livak and Schmittgen, 2001). Primers are given as supplementary Table 1.

## 7. PCR-selection and EMSA

PCR selection was performed by incubating 50 µg protein extracts from transfected cells in RIPA (25 mM NaCl, 10 mM Tris-HCl, pH 7.5, 5 mM EDTA, 0.1% NP40 with 1X Sigma protein inhibitor cocktail) with 5.5 µg PoldI-dC and 3 ng of 76-bp oligonucleotides including a central random sequence of 26 bp in 50 µl distilled water. In parallel, 1.5 mg G protein-Dynabeads (Life technologies) were washed twice in PBS (400 µl), after incubation and coupling with 1 µg of the anti-Flag M2 antibody (the flag being the nucleotide sequence encoding the peptide DYKDDDDK). The two were mixed and incubated for 20 min. with agitation, rinsed three times in PBS (400 µl), then beads were resuspended in 30 µl, denatured for 10 min at 100°C and the supernatant was amplified by PCR by using the primers framing the 26 random base pairs. After 3% agarose gel purification of 76-bp bands, the procedure was performed again five times. A control experiment was carried out in parallel with non-flagged STOX1B. The proteins were purified after transfection and STOX1 complexes were enriched by using the anti-flag M2 antibody coupled with magnetic beads before PCR amplification. After cloning and sequencing, analysis was performed using MEME (Bailey et al., 2009) (<http://meme.ncbr.net>) Then the products were cloned in TOPO-TA, colonies were isolated after bacteria transformation, and DNA was miniprep and sequenced before searching for common motifs using MEME (<http://meme-suite.org/tools/meme>).

EMSA involved using the double-stranded biotinylated probes 3X STRE1: biotin-AGAGCCATYTCACGGAGAGCCATYTCACGGAGAGCCATYTCACGGAGAGC-biotin,  
 3XSTRE2: biotin-GCTATGGTGYGAMAGCTATGGTGYGAMAGCTATGGTGYGAMAGCTAT-biotin  
 and the ANXA1-like probe in Figure 7C. The competitors were obtained by using the same

sequences but non-biotinylated for the specific competitors and a mutated double-strand STRE1 (3XmutSTRE1):

**AGAGCCACYTCATGGAGAGCCACYTCATGGAGAGCCACYTCATGGAGAGC.**

The experiments were performed with an EMSA kit and the Chemiluminescent Nucleic Acid Detection Module of Thermo Scientific, following the provider's advice.

#### 8. Cloning of fragments in luciferase vectors and luciferase assays

Relevant DNA fragments (HMGN1 promoter, STRE1 and STRE2 polymers) were synthesized with linkers or amplified with linkers by using KAPA hifi Polymerase (KAPA Biosystems, Boston) and cloned in pGL3 basic in the HindIII restriction site. HMGN1 promoter primers were **cgataagcttCGCTCACCTTCCTCTTGGGCAT** and **cgataagcttAGGAAGGAAGGAAGTTACACAGA** (amplification product 831 bp, from 788 bp 5' of HMGN1), **cgataagcttTATCTCCATCCCTGCCACTTAA** and **cgataagcttCTCGCTTTACTTACAGCTGACAA** (amplification product of 2192 bp, from 1661 bp 5' of HMGN1). The plasmids were transfected in JEG-3 cells in 24-well plates by using a combination of the pCMX plasmids overexpressing STOX1A, STOX1B, or the empty pCMX (400 ng), 10 ng Renilla vector and 590 ng promoter-reporter vector by using Lipofectamin 2000 (Thermo Fisher Scientific, Montigny-Le-Bretonneux, France), following the manufacturer's advice. After 48 hr, the proteins were collected in 100  $\mu$ L Passive Lysis Buffer, and the Renilla and Luciferase activity were measured at 20  $\mu$ L with an automated plate reader for each sample, to calculate the ratio of fluorescence and normalize the luciferase activity with renilla activity. The inductions were normalized again relative to the level of modification of pcDNA3. For in vitro methylation of cloned promoters such as HMGN1 the plasmid was treated with the CpG Methyltransferase M.SssI (New England Biolabs) following the manufacturer's protocol.

#### 9. Chromatin immunoprecipitation

ChIP involved JEG-3 cells transfected with pCMX-6flag-STOX1A, pCMX-4flag-STOX1B or empty pCMX as described previously. Between  $10^6$  to  $3.10^6$  cells were used at 24 hr post-transfection, rinsed in PBS, and cross linked with 1% paraformaldehyde (Sigma-Aldrich), 10 min at room temperature. Then the crosslink was interrupted by incubation of glycine 125 mmol/L for 5 min at room temperature. The cells were then scraped in PBS, rinsed twice in PBS by centrifugation at 1000g at 4°C. The pellets were used or dropped in liquid nitrogen and stored at -80°C. Nuclei were recovered after resuspension in 50 mmol/L HEPES/KOH, pH 7.5, 0,14 mol/L NaCl, 5 mmol/L EDTA, pH 7.5, 0.1% NaDeoxycholate) with a SIGMA proteases inhibitor cocktail with PMSF 1 mmol/L and Aprotinine 50  $\mu$ g/mL (Euromedex). The samples were centrifuged at 20000g (4°C, 10 min) and the supernatant was eliminated. The nuclei-enriched pellet was resuspended in the same buffer with 1% Triton X-100, with passages through a G26 syringe, then agitated for 30 min at 4°C. Sonication involved using a Bioruptor Pico (Diagenode) for 15-40 cycles for 30 s ON – 30 s OFF. To obtain fragments ranging from 150 to 300 bp. q-PCR was performed on the immunoprecipitate and supernatant with the primers **WNT2Prom1**, **CAGCAAACCCATGGAGTTCT**, and **WNT2BProm2** **CCCTCCATCTCAGCATCAGT**; **F3Prom1**, **TGAGGGTCAGTTGG**, and **F3Prom2** **CACAGAGCTGCAGATGTCAC**; **HMGN1Prom1**, **CTTAATTGATCCCGGACCCC**, and **HMGNProm2**, **CGGCTTCAAACCTACCGTGA**. Two microsatellites were controls (D7S820 and D8S1179), with average qPCR Ct used as a calibrator.

#### 10. Statistics

In the different experiment, statistics were based on parametric tests, mostly ANOVA followed by post-hoc Student Neuman-Keuls tests using the StatistiXL add-in of Excel.



**References:**

GascoinLachambre, G., Buffat, C., Rebourcet, R., Chelbi, S.T., Rigourd, V., Mondon, F., Mignot, T.M., Legras, E., Simeoni, U., Vaiman, D., et al., 2010. Cullins in human intra-uterine growth restriction: expressional and epigenetic alterations. *Placenta* 31, 151–157.

Livak, K.J., Schmittgen, T.D., 2001. Analysis of relative gene expression data using real-time quantitative PCR and the  $2^{-\Delta\Delta C(T)}$  Method. *Methods* 25, 402–408.